The company now expects $650 million to $700 million in revenue ... paired with milestone payments and royalties for 20 years ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Eric Joseph has given his Sell rating due to a combination of factors affecting Novavax’s current and future performance. One major concern is the company’s underwhelming market share for its COVID ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

"We were hopeful to get a larger market share this year," Novavax CEO John Jacobs said in an interview, adding the company ...

During the third quarter, Novavax entered into a material transfer agreement with a leading pharmaceutical company to ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax Inc. closed $15.40 short of its 52-week high ($23.86), which the company achieved on June 6th. Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated ...